Perry Karsen

Karsen seerved as CEO of the Celgene Cellular Therapeutics division of Celgene Corporation and was EVP and COO of Celgene Corporation. Previously, he was president and CEO of Pearl Therapeutics Inc., and held executive positions at Human Genome Sciences Inc., Bristol-Myers Squibb Co., Gementech Inc., and Abbott Laboratories. He currently serves on the boards of Jounce Therapeutics and Nitrome Biosciences.

  • March 2021

Added to: Graphite Bio - S. San Francisco, CA

Graphite Bio is a next-generation gene editing company focused on therapies that harness targeted DNA integration to treat or cure serious diseases. The company is leveraging its targeted DNA platform to advance a portfolio of transformative treatments with potential for saving and dramatically improving patients' lives.